Pfizer beats first quarter estimates on strong product growth By Investing.com

Pfizer posted Q1 adjusted EPS of $0.75, beating consensus by $0.03, on revenue of $14.5 billion versus $13.84 billion expected. Ex-COVID product revenue grew 7% operationally, led by Padcev (+39%), Eliquis (+8%), oncology biosimilars (+52%), and Nurtec (+41%), while Comirnaty and Paxlovid declined 59% and 63%, respectively. Pfizer reaffirmed 2026 guidance of $59.5 billion-$62.5 billion in revenue and $2.80-$3.00 adjusted EPS, though the midpoint EPS of $2.90 remains below the $2.96 consensus.

Analysis

The core signal is not the beat itself; it is that management is leaning on non-COVID launched products to keep the equity narrative intact while the Street is still paying for a rebound in durability. That matters because the revenue mix is improving, but the earnings power is still being capped by an aging franchise and by guidance that quietly embeds only modest acceleration from here. In other words, the market has to decide whether this is the first inning of a re-rating or just a temporary stabilization inside a secularly slower asset.

The second-order read-through is competitive: strong uptake in oncology and obesity-adjacent assets implies Pfizer is still relevant in higher-growth therapeutic categories, but the benefits are likely to accrue unevenly across the peer set. Large-cap pharma with cleaner growth pipelines and less COVID drag should trade as relative winners if investors conclude Pfizer’s mix shift is real; however, contract manufacturers, logistics, and channel partners tied to mature primary-care brands are likely to see less enthusiasm if capital shifts away from legacy spend toward launch execution.

The main risk is that the market fixes on the headline beat and misses the more important issue: the guidance midpoint remains below consensus, so any post-earnings strength can fade once analysts push numbers through. Over the next 1-3 months, the stock is vulnerable to a “good quarter, bad revision” pattern unless pipeline readouts convert into a visible probability-weighted earnings step-up. The contrarian view is that the multiple may already be discounting too much COVID decay; if the launch portfolio keeps compounding at a low-double-digit rate, the stock does not need blockbuster pipeline success to work from here.

For the next 6-12 months, the key catalyst is whether upcoming phase 3 and mid-stage data can justify a higher terminal growth assumption, not whether the current quarter beats by a few cents. Absent that, this remains a valuation and capital-allocation story rather than a pure fundamental momentum story.

Key Decisions for Investors

• Maintain a tactical long PFE only into pullbacks, with a 1-3 month horizon; upside is capped unless pipeline data surprises, while downside is limited by a still-supportive dividend and stabilizing launch mix.
• Sell upside via covered calls or call spreads on PFE into post-earnings strength; risk/reward favors monetizing any relief rally because consensus revisions are more likely to be flat-to-down than materially up.
• Pair trade: long a higher-quality large-cap pharma with cleaner growth visibility against short PFE over 3-6 months; the trade benefits if the market rotates toward names with less legacy revenue drag and more durable EPS trajectory.
• If owning PFE for 12 months, require confirmation of successive launch-quarter acceleration before adding; otherwise keep position size neutral, since the stock can stagnate even with operational improvement if guidance remains sub-consensus.